FY2025 EPS Estimates for NTLA Decreased by Chardan Capital

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at Chardan Capital dropped their FY2025 earnings estimates for Intellia Therapeutics in a research report issued on Monday, November 18th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of ($4.14) for the year, down from their previous estimate of ($4.02). Chardan Capital has a “Buy” rating and a $91.00 price target on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.13) per share.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. The firm’s quarterly revenue was down 24.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.38) EPS.

A number of other research analysts have also recently commented on NTLA. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Oppenheimer lowered their price objective on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Robert W. Baird cut their target price on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Finally, William Blair reiterated a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $54.94.

Intellia Therapeutics Stock Down 7.1 %

Shares of Intellia Therapeutics stock opened at $13.12 on Thursday. Intellia Therapeutics has a 52 week low of $12.82 and a 52 week high of $34.87. The business’s fifty day simple moving average is $18.40 and its 200-day simple moving average is $21.91.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its stake in Intellia Therapeutics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after acquiring an additional 98,865 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in Intellia Therapeutics during the 2nd quarter worth approximately $679,000. American Century Companies Inc. increased its position in Intellia Therapeutics by 23.8% during the second quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock worth $7,397,000 after buying an additional 63,550 shares during the period. Comerica Bank lifted its stake in Intellia Therapeutics by 853.6% in the first quarter. Comerica Bank now owns 37,105 shares of the company’s stock valued at $1,021,000 after buying an additional 33,214 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Intellia Therapeutics by 8.9% in the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after acquiring an additional 746,263 shares during the period. 88.77% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.